Provectus Pharmaceuticals, Inc. Analyst Research R
Post# of 108
Posted On: 01/22/2014 7:28:03 AM
Provectus Pharmaceuticals, Inc. Analyst Research Report
NEW YORK, Jan. 22, 2014 /PRNewswire/ -- Provectus Pharmaceuticals (OTC: PVCT), Inc., is a development-stage pharmaceutical company, that engages in developing pharmaceuticals for oncology and dermatology indications. The company's product line includes PV-10, a Phase II study completed drug candidate for metastatic melanoma, a Phase I study completed candidate for breast cancer, and a Phase I protocol expansion candidate for liver metastasis; and PH-10, a Phase IIc randomized study initiated drug candidate for the treatment of psoriasis, and Phase II study completed candidate for atopic dermatitis. It also develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. In addition, the company develops over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products.
The full analyst research report entails Key features of the Global Pharmaceuticals Industry, Porter's Five Forces, U.S Food and Drug Administration's (FDA) Approval process, Product portfolio, Status of PV-10, value of the company and analyst summary. The comprehensive analyst research report can be viewed in its entirety with price target and analyst recommendation by using this link: http://bit.ly/AnalystResearchReportPVCT copy and paste to browser may be required
EDITOR NOTES:
Information in this release is fact checked and produced on a best efforts basis and reviewed by Osman Ghani, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcapstreet.com.
For any urgent concerns or inquiries, please contact us at compliance@smallcapstreet.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@smallcapstreet.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared Small Cap Street, LLC and authored by Osman Ghani, CFA. An outsourced research services provider represented by Osman Ghani, CFA, has only reviewed the information provided by Small Cap Street, LLC in this article or report. Small Cap Street, LLC is not entitled to veto, interfere or alter the articles, documents or report once reviewed by the outsourced research provider represented by Osman Ghani, CFA.
NOT FINANCIAL ADVICE
Small Cap Street, LLC makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Small Cap Street, LLC is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Small Cap Street, LLC whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street, LLC expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street, LLC does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Small Cap Street, LLC
SOURCE Small Cap Street, LLC
Copyright 2014 PR Newswire
NEW YORK, Jan. 22, 2014 /PRNewswire/ -- Provectus Pharmaceuticals (OTC: PVCT), Inc., is a development-stage pharmaceutical company, that engages in developing pharmaceuticals for oncology and dermatology indications. The company's product line includes PV-10, a Phase II study completed drug candidate for metastatic melanoma, a Phase I study completed candidate for breast cancer, and a Phase I protocol expansion candidate for liver metastasis; and PH-10, a Phase IIc randomized study initiated drug candidate for the treatment of psoriasis, and Phase II study completed candidate for atopic dermatitis. It also develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. In addition, the company develops over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products.
The full analyst research report entails Key features of the Global Pharmaceuticals Industry, Porter's Five Forces, U.S Food and Drug Administration's (FDA) Approval process, Product portfolio, Status of PV-10, value of the company and analyst summary. The comprehensive analyst research report can be viewed in its entirety with price target and analyst recommendation by using this link: http://bit.ly/AnalystResearchReportPVCT copy and paste to browser may be required
EDITOR NOTES:
Information in this release is fact checked and produced on a best efforts basis and reviewed by Osman Ghani, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcapstreet.com.
For any urgent concerns or inquiries, please contact us at compliance@smallcapstreet.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@smallcapstreet.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared Small Cap Street, LLC and authored by Osman Ghani, CFA. An outsourced research services provider represented by Osman Ghani, CFA, has only reviewed the information provided by Small Cap Street, LLC in this article or report. Small Cap Street, LLC is not entitled to veto, interfere or alter the articles, documents or report once reviewed by the outsourced research provider represented by Osman Ghani, CFA.
NOT FINANCIAL ADVICE
Small Cap Street, LLC makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Small Cap Street, LLC is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Small Cap Street, LLC whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street, LLC expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street, LLC does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Small Cap Street, LLC
SOURCE Small Cap Street, LLC
Copyright 2014 PR Newswire
(0)
(0)New World Gold Cp (NWGC) Stock Research Links
Scroll down for more posts ▼